The proposed application represents a comprehensive plan of three projects to improve the capacity of existing tests for pancreatic cancer, and to validate novel biomarkers discovered as part of collaborative efforts during the previous phase of the EDRN. The first project further develops a broad based diagnostic test for pancreatic cancer that enhances the CA19-9 test and incorporates elements of early detection of cancer by detecting autoantibodies to tumor specific glycopeptide structures found on mucins. The earliest premalignant and malignant lesions in the pancreas express MUCI, MUC4, MUC5ac, MUC16, and MUC17 with truncated O-linked structures attached (Tn, sialyl Tn, T) but may not produce a sufficient amount to be detected in serum. Instead, autoantibodies to these specific structures are produced at sufficiently high concentrations to be detected. As lesions progress mucins are detected in circulation, initially as immune complexes with the autoantibodies, and in later stages in the absence of immune complexes. This overall hypothesis will be tested by developing a set of three integrated tests for serum: a test that quantifies autoantibodies, a test that quantifies immune complexes, and a test that quantifies circulating mucins for both oligosaccharide and core protein (on the same molecule). A complementary study in collaboration with Dr. Sam Hanash will identify non-mucin proteins that carry Tn and sialyl Tn antigens and evaluate autoantibodies to these proteins. The second project led by Dr. Surinder Batra proposes to further develop a novel analytical test that shows enhanced sensitivity for detection mucin type glycoprotein (which can be difficult to detect using conventional techniques) using surface enhanced Raman spectroscopy (SERS). This technique will be used to develop an assay for multiple biomarkers in serum. The third project, led by Dr. Schmittgen and in collaboration with Dr. Hollingsworth, will undertake discovery of potential miRNA biomarkers in plasma and urine of patients with different stages of pancreatic cancer and evaluate the prognostic utility for patients with resected pancreatic cancer of evaluating the tissue expression of a set of microRNAs that are associated with early metastasis of pancreatic cancer.

Public Health Relevance

The early detection of pancreatic cancer would increase the percentage of patients eligible for curative resection, and thereby significantly improve the fraction and longevity of survivors of this disease, which is among the most lethal of cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA111294-08
Application #
8320740
Study Section
Special Emphasis Panel (ZCA1-SRLB-C (M1))
Program Officer
Rinaudo, Jo Ann S
Project Start
2004-09-27
Project End
2015-06-30
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
8
Fiscal Year
2012
Total Cost
$594,573
Indirect Cost
$133,769
Name
University of Nebraska Medical Center
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
168559177
City
Omaha
State
NE
Country
United States
Zip Code
68198
Clausen, Thomas Mandel; Pereira, Marina Ayres; Al Nakouzi, Nader et al. (2016) Oncofetal Chondroitin Sulfate Glycosaminoglycans Are Key Players in Integrin Signaling and Tumor Cell Motility. Mol Cancer Res 14:1288-1299
Joshi, Suhasini; Cruz, Eric; Rachagani, Satyanarayana et al. (2016) Bile acids-mediated overexpression of MUC4 via FAK-dependent c-Jun activation in pancreatic cancer. Mol Oncol 10:1063-77
Pai, Priya; Rachagani, Satyanarayana; Dhawan, Punita et al. (2016) Mucins and Wnt/β-catenin signaling in gastrointestinal cancers: an unholy nexus. Carcinogenesis 37:223-32
Vaz, Arokia Priyanka; Deb, Shonali; Rachagani, Satyanarayana et al. (2016) Overexpression of PD2 leads to increased tumorigenicity and metastasis in pancreatic ductal adenocarcinoma. Oncotarget 7:3317-31
Pai, Priya; Rachagani, Satyanarayana; Lakshmanan, Imayavaramban et al. (2016) The canonical Wnt pathway regulates the metastasis-promoting mucin MUC4 in pancreatic ductal adenocarcinoma. Mol Oncol 10:224-39
Krishn, Shiv Ram; Kaur, Sukhwinder; Smith, Lynette M et al. (2016) Mucins and associated glycan signatures in colon adenoma-carcinoma sequence: Prospective pathological implication(s) for early diagnosis of colon cancer. Cancer Lett 374:304-14
Fink, Darci M; Steele, Maria M; Hollingsworth, Michael A (2016) The lymphatic system and pancreatic cancer. Cancer Lett 381:217-36
Chugh, Seema; Meza, Jane; Sheinin, Yuri M et al. (2016) Loss of N-acetylgalactosaminyltransferase 3 in poorly differentiated pancreatic cancer: augmented aggressiveness and aberrant ErbB family glycosylation. Br J Cancer 114:1376-86
Joshi, S; Kumar, S; Ponnusamy, M P et al. (2016) Hypoxia-induced oxidative stress promotes MUC4 degradation via autophagy to enhance pancreatic cancer cells survival. Oncogene 35:5882-5892
Hanson, Ryan L; Brown, Roger B; Steele, Maria M et al. (2016) Identification of FRA-1 as a novel player in pancreatic cancer in cooperation with a MUC1: ERK signaling axis. Oncotarget 7:39996-40011

Showing the most recent 10 out of 167 publications